Holen Sie sich die Stockscreener-App
12.81
3.83%
-0.51
Schlusskurs vom Vortag:
$13.32
Offen:
$13.32
24-Stunden-Volumen:
184.07K
Relative Volume:
1.10
Marktkapitalisierung:
$433.78M
Einnahmen:
$59,000
Nettoeinkommen (Verlust:
$-21.81M
KGV:
-1.1697
EPS:
-10.9518
Netto-Cashflow:
$-18.07M
1W Leistung:
+1.83%
1M Leistung:
-0.62%
6M Leistung:
-20.83%
1J Leistung:
+9.11%
1-Tages-Spanne:
$12.80
$13.33
1-Wochen-Bereich:
$12.49
$13.68
52-Wochen-Spanne:
$9.70
$17.15
Benitec Biopharma Inc Stock (BNTC) Company Profile
Firmenname
Benitec Biopharma Inc
Sektor
Branche
Telefon
(510) 780-0819
Adresse
3940 TRUST WAY, HAYWARD, CA
Vergleichen Sie BNTC mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BNTC
Benitec Biopharma Inc
|
12.81 | 451.04M | 59,000 | -21.81M | -18.07M | -10.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
444.64 | 110.88B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
726.21 | 72.79B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
890.11 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
404.46 | 54.85B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
189.85 | 41.41B | 447.02M | -1.18B | -906.14M | -6.1812 |
Benitec Biopharma Inc Stock (BNTC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-07 | Eingeleitet | TD Cowen | Buy |
| 2024-12-16 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-12-13 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-10-16 | Eingeleitet | Oppenheimer | Outperform |
| 2024-09-12 | Eingeleitet | Guggenheim | Buy |
| 2024-07-22 | Eingeleitet | Leerink Partners | Outperform |
| 2024-06-13 | Eingeleitet | Piper Sandler | Overweight |
| 2020-10-05 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
| 2020-04-20 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2016-02-26 | Herabstufung | Maxim Group | Buy → Hold |
| 2015-12-31 | Bestätigt | Maxim Group | Buy |
| 2015-09-16 | Bestätigt | Maxim Group | Buy |
Alle ansehen
Benitec Biopharma Inc Aktie (BNTC) Neueste Nachrichten
Wall Street Analysts Predict an 87.48% Upside in Benitec Biopharma (BNTC): Here's What You Should Know - Yahoo Finance
Down 25.8% in 4 Weeks, Here's Why You Should You Buy the Dip in Benitec Biopharma (BNTC) - Yahoo Finance
Benitec Biopharma shareholders approve all proposals at annual meeting By Investing.com - Investing.com Nigeria
Benitec Biopharma shareholders approve all proposals at annual meeting - Investing.com
Benitec Biopharma Concludes 2025 Annual Stockholders Meeting - TipRanks
Price-Driven Insight from (BNTC) for Rule-Based Strategy - news.stocktradersdaily.com
Can Benitec Biopharma Inc. stock continue upward trendJuly 2025 Momentum & AI Enhanced Execution Alerts - Newser
Risk Check: Can Benitec Biopharma Inc. stock double in next 5 years - BỘ NỘI VỤ
Big Insider Purchases by Carl Icahn, Mario Gabelli, and Others - AOL.com
Franklin Resources Inc. Cuts Stake in Benitec Biopharma Limited $BNTC - MarketBeat
Why Benitec Biopharma Inc. stock could be next big winner2025 Key Lessons & Weekly Momentum Picks - moha.gov.vn
Can Benitec Biopharma Inc. stock double in next 5 yearsJuly 2025 Drop Watch & High Accuracy Swing Entry Alerts - moha.gov.vn
HC Wainwright Has Optimistic Outlook of BNTC FY2026 Earnings - MarketBeat
What is HC Wainwright's Estimate for BNTC Q2 Earnings? - MarketBeat
Q2 Earnings Estimate for BNTC Issued By HC Wainwright - Defense World
BNTC Analyst Rating Maintained but Price Target Lowered to $32 b - GuruFocus
Benitec BioPharma price target lowered to $32 at H.C. Wainwright By Investing.com - Investing.com UK
Benitec Biopharma (NASDAQ:BNTC) Rating Increased to Hold at Wall Street Zen - Defense World
Benitec Biopharma Shares Surge 20% After FDA Grants Fast Track Status for OPMD Gene Therapy - MSN
(BNTC) Price Dynamics and Execution-Aware Positioning - news.stocktradersdaily.com
Is Benitec Biopharma Inc. stock a smart buy before Fed meetingWeekly Trade Summary & Low Risk Growth Stock Ideas - newser.com
[Form 4] Benitec Biopharma Inc. Insider Trading Activity - Stock Titan
Pattern recognition hints at Benitec Biopharma Inc. upsideJuly 2025 Final Week & Risk Adjusted Buy and Sell Alerts - newser.com
Benitec Biopharma Limited (NASDAQ:BNTC) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Can Benitec Biopharma Inc. stock sustain market leadershipEarnings Miss & Risk Managed Trade Strategies - newser.com
Benitec Biopharma Limited (NASDAQ:BNTC) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
Is Benitec Biopharma Inc. a candidate for recovery play2025 Top Gainers & Trade Opportunity Analysis - newser.com
Is Benitec Biopharma Inc. stock affected by interest rate hikesLong Setup & Reliable Intraday Trade Alerts - newser.com
Strategies to average down on Benitec Biopharma Inc.July 2025 Recap & Technical Buy Zone Confirmations - newser.com
Benitec Biopharma Inc. recovery potential after sell off2025 Buyback Activity & Risk Controlled Stock Alerts - newser.com
Is Benitec Biopharma Inc. stock attractive for growth ETFs2025 Market WrapUp & Risk Controlled Daily Plans - newser.com
Can a trend reversal in Benitec Biopharma Inc. lead to recoveryProfit Target & Community Consensus Trade Alerts - newser.com
Citizens reiterates Market Outperform rating on Benitec BioPharma stock By Investing.com - Investing.com Canada
Real time social sentiment graph for Benitec Biopharma Inc.2025 Market Overview & Fast Moving Market Watchlists - newser.com
Citizens Lifts Benitec Biopharma Inc. (BNTC) Price Target on Topline Results for Oculopharyngeal Muscular Dystrophy Treatment - Finviz
Benitec Biopharma Reports Increased Quarterly Loss Amid Rising Expenses - MSN
Hedge funds investors have a lot riding on Benitec Biopharma Inc. (NASDAQ:BNTC) with 37% ownership - Yahoo Finance
Citizens reiterates Market Outperform rating on Benitec BioPharma stock - Investing.com India
Benitec Biopharma’s SWOT analysis: gene therapy stock shows promise amid sector headwinds - Investing.com Nigeria
Benitec Biopharma’s SWOT analysis: gene therapy stock shows promise amid sector headwinds By Investing.com - Investing.com South Africa
Finanzdaten der Benitec Biopharma Inc-Aktie (BNTC)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.45%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):